Analysts at Leerink Swann started coverage on shares of Aclaris Therapeutics Inc. (NASDAQ:ACRS) in a report released on Tuesday. The firm set an “outperform” rating on the stock.
ACRS has been the topic of several other research reports. Zacks Investment Research upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 18th. Jefferies Group upped their target price on Aclaris Therapeutics from $23.00 to $31.00 and gave the company a “buy” rating in a report on Monday, September 19th. Finally, JMP Securities initiated coverage on Aclaris Therapeutics in a report on Friday, September 30th. They issued an “outperform” rating and a $34.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Aclaris Therapeutics presently has an average rating of “Buy” and an average target price of $32.50.
Shares of Aclaris Therapeutics (NASDAQ:ACRS) traded up 4.21% on Tuesday, reaching $29.22. 32,872 shares of the company’s stock were exchanged. The company’s market capitalization is $626.24 million. Aclaris Therapeutics has a 12 month low of $14.12 and a 12 month high of $33.88. The firm’s 50 day moving average price is $23.20 and its 200-day moving average price is $21.47.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Thursday, November 3rd. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.66) by $0.16. On average, equities analysts anticipate that Aclaris Therapeutics will post ($2.38) EPS for the current year.
In related news, insider Kamil Ali-Jackson sold 3,912 shares of the stock in a transaction that occurred on Wednesday, October 26th. The stock was sold at an average price of $21.83, for a total value of $85,398.96. Following the transaction, the insider now owns 79,869 shares in the company, valued at $1,743,540.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Ventures Fund Vii L.P. Vivo sold 907,828 shares of the stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $23.03, for a total value of $20,907,278.84. The disclosure for this sale can be found here. 46.40% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in ACRS. Rock Springs Capital Management LP increased its position in Aclaris Therapeutics by 1.6% in the third quarter. Rock Springs Capital Management LP now owns 1,016,000 shares of the company’s stock worth $26,020,000 after buying an additional 16,000 shares in the last quarter. FIL Ltd purchased a new position in Aclaris Therapeutics during the second quarter worth approximately $13,801,000. Vanguard Group Inc. increased its position in Aclaris Therapeutics by 147.6% in the second quarter. Vanguard Group Inc. now owns 419,184 shares of the company’s stock worth $7,743,000 after buying an additional 249,888 shares in the last quarter. BlackRock Fund Advisors increased its position in Aclaris Therapeutics by 13.6% in the third quarter. BlackRock Fund Advisors now owns 266,552 shares of the company’s stock worth $6,826,000 after buying an additional 31,856 shares in the last quarter. Finally, State Street Corp increased its position in Aclaris Therapeutics by 64.8% in the second quarter. State Street Corp now owns 120,010 shares of the company’s stock worth $2,217,000 after buying an additional 47,179 shares in the last quarter. Hedge funds and other institutional investors own 72.10% of the company’s stock.
About Aclaris Therapeutics